1
|
Coleman M, Orvis A, Brokaw A, Furuta A, Sharma K, Quach P, Bhullar A, Sanghavi R, Nguyen S, Sweeney E, Seepersaud R, Armistead B, Adams Waldorf KM, Rajagopal L. GBS hyaluronidase mediates immune suppression in a TLR2/4- and IL-10-dependent manner during pregnancy-associated infection. mBio 2023; 14:e0204923. [PMID: 37747229 PMCID: PMC10653848 DOI: 10.1128/mbio.02049-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 08/07/2023] [Indexed: 09/26/2023] Open
Abstract
IMPORTANCE Bacteria such as GBS can cause infections during pregnancy leading to preterm births, stillbirths, and neonatal infections. The interaction between host and bacterial factors during infections in the placenta is not fully understood. GBS secretes a hyaluronidase enzyme that is thought to digest host hyaluronan into immunosuppressive disaccharides that dampen TLR2/4 signaling, leading to increased bacterial dissemination and adverse outcomes. In this study, we show that GBS HylB mediates immune suppression and promotes bacterial infection during pregnancy that requires TLR2, TLR4, and IL-10. Understanding the interaction between host and bacterial factors can inform future therapeutic strategies to mitigate GBS infections.
Collapse
Affiliation(s)
- Michelle Coleman
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Austyn Orvis
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Alyssa Brokaw
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
- Department of Global Health, University of Washington, Seattle, Washington, USA
| | - Anna Furuta
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
- Department of Global Health, University of Washington, Seattle, Washington, USA
| | - Kavita Sharma
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Phoenicia Quach
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Avneet Bhullar
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Rhea Sanghavi
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Shayla Nguyen
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Erin Sweeney
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Ravin Seepersaud
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Blair Armistead
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Kristina M. Adams Waldorf
- Department of Global Health, University of Washington, Seattle, Washington, USA
- Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
| | - Lakshmi Rajagopal
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
- Department of Global Health, University of Washington, Seattle, Washington, USA
- Department of Pediatrics, University of Washington, Seattle, Washington, USA
| |
Collapse
|
2
|
du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, Khemissa-Akouz F, Perrier H, Bouché O, Paoletti X, Le Tourneau C. Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens. ESMO Open 2023; 8:101616. [PMID: 37542912 PMCID: PMC10485393 DOI: 10.1016/j.esmoop.2023.101616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 07/07/2023] [Accepted: 07/08/2023] [Indexed: 08/07/2023] Open
Abstract
BACKGROUND Precision medicine trials disrupted the paradigm of randomized controlled trials in large populations. Patient selection may be based on molecular alterations rather than on primary tumor location. In small patient populations, the growth modulation index (GMI) has been developed to evaluate treatment efficacy by using each patient as its own control. The FFCD 0307 randomized phase III trial compared two sequences of chemotherapy in advanced gastric cancer, which represents a unique opportunity to evaluate the relevance of the GMI. PATIENTS AND METHODS In the FFCD 0307 trial, patients with advanced gastric cancer were randomized between two chemotherapy sequences [ECX followed by FOLFIRI at disease progression (arm A) versus FOLFIRI followed by ECX (arm B)]. GMI was defined as the ratio of the progression-free survival on second treatment (PFS2) to the time to progression on first treatment (TTP1). Sequence benefit was defined as a GMI exceeding 1.3 (GMI-high). GMI was correlated with overall survival (OS). OS1 and OS2 were measured from first randomization and second-line failure to death. RESULTS Four hundred and sixteen patients were randomized (209 in arm A, 207 in arm B). One hundred and seventy-five patients (42%) received the two sequences and were assessable for GMI (97 in arm A, 79 in arm B). The median GMI was higher in arm A than in arm B (0.62 versus 0.47, P = 0.04). Patients with a high GMI had a longer OS1 (median 14.9 versus 11.5 months, NS). Median OS2 was doubled in the GMI-high group (3.4 versus 1.6 months, NS). CONCLUSION GMI analyses suggest that ECX followed by FOLFIRI might represent a better therapeutic strategy than FOLFIRI followed by ECX. High GMI was associated with prolonged survival.
Collapse
Affiliation(s)
- P du Rusquec
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U900 Research Unit, PSL Research University, Institut Curie, Saint Cloud, France.
| | - R Guimbaud
- Medical Oncology, CHU de Toulouse, Toulouse, France
| | - K Le Malicot
- Department of Biostatistics, Fédération Francophone de la Cancérologie Digestive, Dijon FFCD, Dijon, France; EPICAD INSERM LNC-UMR 1231, Bourgogne Franche-Comté University, Dijon, France
| | - J-M Gornet
- Gastroenterology, Hôpital Saint-Louis, Paris, France
| | - S Nguyen
- Medical Oncology, CH de Pau, Pau, France
| | - T Lecomte
- Department of Hepatogastroenterology and Digestive Oncology, University Hospital of Tours, Tours, France
| | | | - H Perrier
- Medical Oncology, Hôpital Saint-Joseph, Marseille, France
| | - O Bouché
- Gastroenterology and Digestive Oncology, CHU de Reims, Hôpital Robert Debré, Reims, France
| | - X Paoletti
- INSERM U900 Research Unit, PSL Research University, Institut Curie, Saint Cloud, France
| | - C Le Tourneau
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U900 Research Unit, PSL Research University, Institut Curie, Saint Cloud, France
| |
Collapse
|
3
|
Furuta A, Coleman M, Casares R, Seepersaud R, Orvis A, Brokaw A, Quach P, Nguyen S, Sweeney E, Sharma K, Wallen G, Sanghavi R, Mateos-Gil J, Cuerva JM, Millán A, Rajagopal L. CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog. PLoS Pathog 2023; 19:e1011490. [PMID: 37384812 DOI: 10.1371/journal.ppat.1011490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 06/14/2023] [Indexed: 07/01/2023] Open
Abstract
Although hemolytic lipids have been discovered from many human pathogens including Group B Streptococcus (GBS), strategies that neutralize their function are lacking. GBS is a leading cause of pregnancy-associated neonatal infections, and adult GBS infections are on the rise. The GBS hemolytic lipid toxin or granadaene, is cytotoxic to many immune cells including T and B cells. We previously showed that mice immunized with a synthetic nontoxic analog of granadaene known as R-P4 had reduced bacterial dissemination during systemic infection. However, mechanisms important for R-P4 mediated immune protection was not understood. Here, we show that immune serum from R-P4-immunized mice facilitate GBS opsonophagocytic killing and protect naïve mice from GBS infection. Further, CD4+ T cells isolated from R-P4-immunized mice proliferated in response to R-P4 stimulation in a CD1d- and iNKT cell-dependent manner. Consistent with these observations, R-P4 immunized mice lacking CD1d or CD1d-restricted iNKT cells exhibit elevated bacterial burden. Additionally, adoptive transfer of iNKT cells from R-P4 vaccinated mice significantly reduced GBS dissemination compared to adjuvant controls. Finally, maternal R-P4 vaccination provided protection against ascending GBS infection during pregnancy. These findings are relevant in the development of therapeutic strategies targeting lipid cytotoxins.
Collapse
Affiliation(s)
- Anna Furuta
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - Michelle Coleman
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Raquel Casares
- Department of Organic Chemistry, University of Granada, Granada, Spain
| | - Ravin Seepersaud
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Austyn Orvis
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Alyssa Brokaw
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - Phoenicia Quach
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Shayla Nguyen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Erin Sweeney
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Kavita Sharma
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Grace Wallen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
| | - Rhea Sanghavi
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - Jaime Mateos-Gil
- Department of Organic Chemistry, University of Granada, Granada, Spain
| | | | - Alba Millán
- Department of Organic Chemistry, University of Granada, Granada, Spain
| | - Lakshmi Rajagopal
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Pediatrics, University of Washington, Seattle, Washington, United States of America
| |
Collapse
|
4
|
Brédy S, Campion A, Nguyen S, Martinot A, Pouessel G. Pediatric private practice in the Nord-Pas-de-Calais region: Demographics, organization, and challenges. Arch Pediatr 2023:S0929-693X(23)00085-4. [PMID: 37286424 DOI: 10.1016/j.arcped.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 01/02/2023] [Accepted: 04/29/2023] [Indexed: 06/09/2023]
Abstract
While the needs for pediatric care are increasing and becoming more diverse, pediatric private practice in France is encountering difficulties linked to a growing medical demographic deficit. The objective of this study was to give an overview of pediatric private practice in the Nord-Pas-de-Calais region and to describe the main challenges encountered. METHODS For this descriptive observational survey, private practice pediatricians in the Nord-Pas-de-Calais region filled out an online questionnaire between April 2019 and October 2020. RESULTS The response rate was 64%. Most respondents practiced in an urban area (87%) and shared the practice with other physicians (59%). A majority (85%) had previously worked in hospital; 65% reported training in a subspecialty. Overall, 48% had other professional activities; 28% worked night shifts and 96% accepted urgent requests for consultations. A total of 33% reported having difficulties contacting specialists for consults, and 46% had difficulties in obtaining written reports of their patients' hospitalizations. All respondents participated in a form of ongoing medical education. The main difficulties were: lack of information about how to found a private practice (68%), lack of personal time (61%), balance between medical and administrative work (59%), and an excess of patients to care for (57%). The main satisfactions were: trusting relationships with patients (98%), freedom in their choice of practice (85%), and the diversity of problems and situations encountered (68%). CONCLUSION Our study underlines that private practice pediatricians are involved in healthcare provision, in particular regarding ongoing medical training, subspecialties, and continuity of care. It also highlights the problems encountered and the possible improvements: developing better communication between private practice and hospitals, reinforcing training during residency, and highlighting the importance and complementarity of private practice in children's healthcare.
Collapse
Affiliation(s)
- S Brédy
- Centre Hospitalier de Roubaix, Service de Pédiatrie, 11 Bd Lacordaire, 59100 Roubaix, France
| | - A Campion
- Cabinet de Pédiatrie Libérale, 92 Bd du Général de Gaulle, 59100 Roubaix, France
| | - S Nguyen
- Hôpital Roger Salengro, Service de Neurologie Pédiatrique, Av du Professeur Emile Laine, 59037 Lille, France
| | - A Martinot
- CHRU Lille, Service des Urgences Pédiatriques, Av du Professeur Emile Laine, 59037 Lille, France
| | - G Pouessel
- Centre Hospitalier de Roubaix, Service de Pédiatrie, 11 Bd Lacordaire, 59100 Roubaix, France.
| |
Collapse
|
5
|
Sklavos T, Nguyen S, Sutcliffe S. Characteristics and outcomes of patients presenting with out of hospital cardiac arrest to a regional hospital. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Out of hospital cardiac arrest (OHCA) carries a high rate of mortality and can be due to cardiac or non-cardiac causes. We reviewed consecutive patients presenting with OHCA to the emergency department of a regional hospital in Australia, between January 2019 and March 2022. Medical records were reviewed to assess presenting rhythm, final diagnosis, risk factors known at time of presentation, results of cardiac investigations and survival to hospital discharge.
Results
Over the study period, 107 patients presented with cardiac arrest, with an average age of 67 years (range 29 to 95 years). Most patients were male (70, 67%), although in those with a non-cardiac cause identified only 53% were male. An underlying cardiac cause was identified in 50 (47%), a non-cardiac cause was identified in 18 (17%), and 39 (36%) had no identifiable cause. The most common cardiac causes were ST-elevation myocardial infarction (18, 36%), followed by non-ischaemic cardiomyopathy (9, 18%) and scar-related arrhythmia (7, 14%). Overall, ischaemic heart disease was responsible for 31 (62%) cases. Coronary angiography was performed in 36 (72%) of cardiac cases. Those who were diagnosed with ST-elevation myocardial infarction had an average time from presentation to coronary angiography of 61 minutes while the average was 38 hours for all patients presenting with OHCA. The most common presenting rhythm was ventricular fibrillation (39, 38%). The overall mortality rate was 61% for all OHCA. Among those with a cardiac cause, a non-cardiac cause or no cause identified for the OHCA, the mortality rates were 32%, 87% and 87% respectively. Data published by the regional Ambulance Service show that the survival to discharge from hospital of 39% in our regional hospital is comparable with state-wide outcomes.
Discussion
These data reflect the significant mortality and wide spectrum of disease underlying OHCA, and thus the challenge of managing patients presenting with OHCA. Cardiac disease accounts for almost half of all cases of OHCA, and also encompasses a wide spectrum of disease. However, the mortality in patients with OHCA due to an underlying cardiac cause, while still significant, is better than those patients in whom no cardiac cause is identified.
Collapse
Affiliation(s)
- T Sklavos
- Cairns Hospital , Cairns , Australia
| | - S Nguyen
- Cairns Hospital , Cairns , Australia
| | | |
Collapse
|
6
|
Yu B, Katafiasz TJ, Nguyen S, Allegri G, Finlayson J, Greenhalgh ES, Pinho ST, Pimenta S. Characterizing and predicting the relationship between translaminar fracture toughness and pull-out length distributions under distinct temperatures. Philos Trans A Math Phys Eng Sci 2023; 381:20210220. [PMID: 36403637 DOI: 10.1098/rsta.2021.0220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Accepted: 09/11/2022] [Indexed: 06/16/2023]
Abstract
The translaminar fracture toughness reflects the damage tolerance of a fibre-reinforced composite under longitudinal tension, which often governs the final failure of structures. One of the main energy-dissipation mechanisms that contributes to the translaminar toughness of composites is the fibre pull-out process. The present study aims to quantify and model the statistical distribution of fibre pull-out lengths formed on the translaminar fracture surface of composites, for the first time in the literature; this is done under different temperatures, so that the relationship between pull-out length distributions, micromechanical properties and the translaminar fracture toughness can be established. The fracture surfaces of cross-ply compact tension specimens tested under three different temperatures have been scanned through X-ray computed tomography to quantify the extent of fibre pull-out on the fracture surfaces; the distribution of pull-out lengths showed alarger average and larger variability with an increase in temperature, which also lead to an increase in translaminar fracture toughness. A similar trend has been captured by the proposed analytical model, which predicts the pull-out length distribution based on the analysis of quasi-fractal idealizations of the fracture surface, yielding an overall accuracy of more than 85%. This article is part of the theme issue 'Ageing and durability of composite materials'.
Collapse
Affiliation(s)
- B Yu
- Department of Aeronautics, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
- Department of Mechanical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | - T J Katafiasz
- Department of Aeronautics, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | - S Nguyen
- Department of Aeronautics, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | - G Allegri
- Bristol Composites Institute (ACCIS), University of Bristol, Queen's Building, Bristol BS8 1TR, UK
| | - J Finlayson
- Structural Systems Design, Rolls-Royce plc, Derby, UK
| | - E S Greenhalgh
- Department of Aeronautics, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | - S T Pinho
- Department of Aeronautics, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | - S Pimenta
- Department of Mechanical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| |
Collapse
|
7
|
Heal C, Hsu C, Ho Q, Dougherty S, Ansinelli H, Morrison C, Gay C, Xing J, Nguyen S, Gonzalez V, Stea B, Robbins J. Technology Usage and Impacts by COVID-19 among Patients in a Radiation Oncology Clinic. Int J Radiat Oncol Biol Phys 2022. [PMCID: PMC9595464 DOI: 10.1016/j.ijrobp.2022.07.919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Purpose/Objective(s) Mobile devices provide platforms for consistent and real time symptom tracking for cancer patients, allowing for better symptom reporting and more timely interventions. There is limited research investigating barriers to adoption within the oncology setting and COVID-19 impacts on patent willingness to use health technology. Understanding these issues is key to successful development and implementation. We designed a survey to assess patient willingness and barriers to using mobile devices to report/track symptoms (e-report). Materials/Methods Two cohorts of adult patients completed a 21-question anonymized survey. The survey was administered to clinic patients before (PRE) and 18mo after (POST) the start of the COVID pandemic. Three additional questions were added to POST survey to investigate impacts from COVID. Demographics, technology usage, willingness to report data, barriers to utilization, and changes due to COVID were evaluated using descriptive statistics. Predictors of willingness to e-report, barriers to use, and changes due to the COVID-19 pandemic were analyzed using univariate and multivariate logistic regression (MVA). Results 318 patients completed the survey (PRE= 144 patients; POST= 174 patients) with mean age 65y, 75% Caucasian, 55% male. Altogether, 75% used a smart phone (PRE=66.7%; POST=81.3%; p 0.003), 90% reported home internet access (PRE=87.5%; POST=91.4%; p 0.259), 86% used a computer (PRE=79.2%; POST=90.8%; p 0.004), and 26% used a wearable health tracker (PRE 25.7%; POST 26.4%; p 0.881). On MVA, age>65 (OR 0.32; p 0.001), annual income>50K (OR 2.16; p 0.032), smart phone ownership (OR 4.07; p 0.000), and new/current patient status (OR 2.15; p 0.020) were all significant factors impacting willingness to e- report. Limited tech literacy (p 0.024) and time commitment (p 0.048) were the only significant barriers. Privacy as a barrier was greater in PRE vs POST cohort (OR 2.3 vs OR 1.1) trending toward significance. Nearly all modes of tech usage were greater in POST vs PRE cohort. POST cohort was significantly more willing to e- report (81.1% vs 69.1%; OR 1.91; p 0.016). This remained significant on MVA after adjusting for age, concern for privacy, tech literacy, and patient status (OR 1.88; p 0.026). Furthermore, 51% of POST cohort reported the pandemic directly influenced their willingness to e-report (40% more, 11% less). Conclusion Radiation oncology patients are willing to use mobile technology to report symptoms. Willingness increases with decreasing age, increasing annual income, smartphone ownership, and new/current patient status. Significant barriers include tech literacy and time commitment. Post-pandemic patients are more willing to e-report and list fewer barriers. The COVID-19 pandemic appears to have had a positive impact on technology usage by patients. Efforts to develop and test mobile applications for this population are justified.
Collapse
Affiliation(s)
- C. Heal
- University of Arizona - Department of Radiation Oncology, Tucson, AZ,Corresponding author
| | - C.C. Hsu
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - Q.A. Ho
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - S.T. Dougherty
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - H. Ansinelli
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - C. Morrison
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - C. Gay
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - J.L. Xing
- University of Arizona, Department of Radiation Oncology, Tucson, AZ
| | - S. Nguyen
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - V.J. Gonzalez
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - B. Stea
- University of Arizona - Department of Radiation Oncology, Tucson, AZ
| | - J.R. Robbins
- University of Arizona, Department of Radiation Oncology, Tucson, AZ
| |
Collapse
|
8
|
Ho Q, Heal C, Ansinelli H, Xing J, Nguyen S, Gay C, Robbins J. The Effects of a Radiation Oncology Emergencies Lecture on Initiation of Care, Timeliness of Consultations Placed and Duration of Hospitalization. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Huebner EM, Gudjónsdóttir MJ, Dacanay MB, Nguyen S, Brokaw A, Sharma K, Elfvin A, Hentz E, Rivera YR, Burd N, Shivakumar M, Coler B, Li M, Li A, Munson J, Orvis A, Coleman M, Jacobsson B, Rajagopal L, Adams Waldorf KM. Virulence, phenotype and genotype characteristics of invasive group B Streptococcus isolates obtained from Swedish pregnant women and neonates. Ann Clin Microbiol Antimicrob 2022; 21:43. [PMID: 36229877 PMCID: PMC9560721 DOI: 10.1186/s12941-022-00534-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 09/30/2022] [Indexed: 11/17/2022] Open
Abstract
Group B streptococci (GBS) are bacteria that can cause preterm birth and invasive neonatal disease. Heterogeneous expression of virulence factors enables GBS to exist as both commensal bacteria and to become highly invasive. A molecular epidemiological study comparing GBS bacterial traits, genotype and host characteristics may indicate whether it is possible to predict the risk of perinatal invasive GBS disease and more accurately target intrapartum antibiotic prophylaxis. A total of 229 invasive GBS isolates from Swedish pregnant women or neonates were assessed for virulence and phenotypic traits: hemolysis zone, hemolytic pigment (Granada agar), Streptococcus B Carrot Broth (SBCB) assay, CAMP factor, and hyaluronidase activity. Genes regulating hemolytic pigment synthesis (covR/covS, abx1, stk1, stp1) were sequenced. Of the virulence factors and phenotypes assessed, a Granada pigment or SBCB score ≥ 2 captured more than 90% of EOD isolates with excellent inter-rater reliability. High enzyme activity of hyaluronidase was observed in 16% (36/229) of the invasive GBS isolates and notably, in one case of stillbirth. Hyaluronidase activity was also significantly higher in GBS isolates obtained from pregnant/postpartum individuals versus the stillbirth or neonatal invasive isolates (p < 0.001). Sequencing analysis found that abx1 (g.T106I), stk1 (g.T211N), stp1 (g.K469R) and covS (g.V343M) variants were present significantly more often in the higher (Granada pigment score ≥ 2) versus lower pigmented isolates (p < 0.001, each variant). Among the 203 higher Granada pigment scoring isolates, 22 (10.8%) isolates had 3 of the four sequence variants and 10 (4.9%) had 2 of the four sequence variants. Although heterogeneity in GBS virulence factor expression was observed, the vast majority were more highly pigmented and contained several common sequence variants in genes regulating pigment synthesis. High activity of hyaluronidase may increase risk for stillbirth and invasive disease in pregnant or postpartum individuals. Our findings suggest that testing for GBS pigmentation and hyaluronidase may, albeit imperfectly, identify pregnant people at risk for invasive disease and represent a step towards a personalized medical approach for the administration of intrapartum antibiotic prophylaxis.
Collapse
Affiliation(s)
- Emily M. Huebner
- grid.34477.330000000122986657School of Medicine, University of Washington, Seattle, WA USA ,grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Margrét Johansson Gudjónsdóttir
- grid.8761.80000 0000 9919 9582Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden ,grid.1649.a000000009445082XDepartment of Pediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Matthew B. Dacanay
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Shayla Nguyen
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA
| | - Alyssa Brokaw
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA
| | - Kavita Sharma
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA
| | - Anders Elfvin
- grid.8761.80000 0000 9919 9582Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden ,grid.1649.a000000009445082XDepartment of Pediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Elisabet Hentz
- grid.8761.80000 0000 9919 9582Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden ,grid.1649.a000000009445082XDepartment of Pediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Ysabella Raceli Rivera
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Nicole Burd
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Megana Shivakumar
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Brahm Coler
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA ,grid.30064.310000 0001 2157 6568Elson S. Floyd College of Medicine, Washington State University, Spokane, WA USA
| | - Miranda Li
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA ,grid.21729.3f0000000419368729Columbia University, New York, NY USA
| | - Amanda Li
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA
| | - Jeff Munson
- grid.34477.330000000122986657Department of Psychiatry and Behavior Sciences, University of Washington, Seattle, WA USA
| | - Austyn Orvis
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA
| | - Michelle Coleman
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA
| | - Bo Jacobsson
- grid.1649.a000000009445082XDepartment of Pediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden ,grid.8761.80000 0000 9919 9582Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Lakshmi Rajagopal
- grid.240741.40000 0000 9026 4165Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA USA ,grid.34477.330000000122986657Department of Pediatrics, University of Washington, Seattle, WA USA
| | - Kristina M. Adams Waldorf
- grid.34477.330000000122986657Department of Obstetrics and Gynecology, University of Washington, Seattle, WA USA ,grid.8761.80000 0000 9919 9582Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
10
|
Michaels P, Kung F, Nguyen S, Slover C, Shortridge D, Streit J, Echols R, Takemura M, Yamano Y. 461 In vitro antibacterial activity of cefiderocol against a multinational collection of Pseudomonas aeruginosa isolates from people with cystic fibrosis: SENTRY 2020–2021. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01151-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
11
|
Piliponsky AM, Sharma K, Quach P, Brokaw A, Nguyen S, Orvis A, Saha SS, Samanas NB, Seepersaud R, Tang YP, Mackey E, Bhise G, Gendrin C, Furuta A, Seo AJ, Guga E, Miralda I, Coleman MM, Sweeney EL, Bäuml CA, Imhof D, Snyder JM, Moeser AJ, Rajagopal L. Mast cell derived factor XIIIA contributes to sexual dimorphic defense against group B Streptococcal infections. J Clin Invest 2022; 132:157999. [PMID: 36006736 PMCID: PMC9566924 DOI: 10.1172/jci157999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Accepted: 08/23/2022] [Indexed: 11/17/2022] Open
Abstract
Invasive bacterial infections remain a major cause of human morbidity. Group B streptococcus (GBS) are Gram-positive bacteria that cause invasive infections in humans. Here, we show that factor XIIIA–deficient (FXIIIA-deficient) female mice exhibited significantly increased susceptibility to GBS infections. Additionally, female WT mice had increased levels of FXIIIA and were more resistant to GBS infection compared with isogenic male mice. We observed that administration of exogenous FXIIIA to male mice increased host resistance to GBS infection. Conversely, administration of a FXIIIA transglutaminase inhibitor to female mice decreased host resistance to GBS infection. Interestingly, male gonadectomized mice exhibited decreased sensitivity to GBS infection, suggesting a role for gonadal androgens in host susceptibility. FXIIIA promoted GBS entrapment within fibrin clots by crosslinking fibronectin with ScpB, a fibronectin-binding GBS surface protein. Thus, ScpB-deficient GBS exhibited decreased entrapment within fibrin clots in vitro and increased dissemination during systemic infections. Finally, using mice in which FXIIIA expression was depleted in mast cells, we observed that mast cell–derived FXIIIA contributes to host defense against GBS infection. Our studies provide insights into the effects of sexual dimorphism and mast cells on FXIIIA expression and its interactions with GBS adhesins that mediate bacterial dissemination and pathogenesis.
Collapse
Affiliation(s)
- Adrian M Piliponsky
- Department of Global Health, University of Washington, Seattle, United States of America
| | - Kavita Sharma
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Phoenicia Quach
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Alyssa Brokaw
- Department of Global Health, University of Washington, Seattle, United States of America
| | - Shayla Nguyen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Austyn Orvis
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Siddhartha S Saha
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Nyssa Becker Samanas
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Ravin Seepersaud
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Yu Ping Tang
- Departments of Large Animal Clinical Sciences, Physiology, Neuroscience Pro, Michigan State University, East Lansing, United States of America
| | - Emily Mackey
- Departments of Large Animal Clinical Sciences, Physiology, Neuroscience Pro, Michigan State University, East Lansing, United States of America
| | - Gauri Bhise
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Claire Gendrin
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Anna Furuta
- Department of Global Health, University of Washington, Seattle, United States of America
| | - Albert J Seo
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Eric Guga
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Irina Miralda
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States of America
| | - Michelle M Coleman
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Erin L Sweeney
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| | - Charlotte A Bäuml
- Pharmaceutical Biochemistry and Bioanalytics, University of Bonn, Bonn, Germany
| | - Diana Imhof
- Pharmaceutical Biochemistry and Bioanalytics, University of Bonn, Bonn, Germany
| | - Jessica M Snyder
- Department of Comparative Medicine, University of Washington, Seattle, United States of America
| | - Adam J Moeser
- Departments of Large Animal Clinical Sciences, Physiology, Neuroscience Pro, Michigan State University, East Lansing, United States of America
| | - Lakshmi Rajagopal
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States of America
| |
Collapse
|
12
|
Dhedin N, Chevillon F, Castelle M, Lavoipière V, Vasseur L, Dalle JH, Joseph L, Beckerich F, Buchbinder N, Coman T, Garban F, Ferster A, Nguyen S, Boissel N, Arlet JB, Pondarre C. HLA-matched related-donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: comparison of myeloablative and non-myeloablative approaches. Am J Hematol 2022; 97:E359-E362. [PMID: 35802796 DOI: 10.1002/ajh.26656] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 06/29/2022] [Accepted: 07/05/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Nathalie Dhedin
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | - Florian Chevillon
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | | | - Virginie Lavoipière
- Internal Medicine and Clinical Immunology, Conception Hospital, Marseille. France; Internal Medicine, Martigues Hospital, France
| | - Loic Vasseur
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | | | | | | | | | - Tereza Coman
- Department of Hematology, Gustave Roussy Hospital, Villejuif, France
| | | | - Alina Ferster
- Hemato-Oncology and Transplantation Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - S Nguyen
- Department of Hematology, Pitié Salpetrière Hospital, Sorbonne University, Paris, France
| | - Nicolas Boissel
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | - Jean-Benoit Arlet
- French Sickle Cell Referral Center, Internal Medicine Department, Georges Pompidou European Hospital, and Université de Paris, Paris, France
| | - Corinne Pondarre
- Pediatric Department, Sickle Cell Referral Center, Centre Hospitalier Intercommunal de Créteil, France and Inserm U955, Université Paris XII, Créteil, France
| | | |
Collapse
|
13
|
Brokaw A, Nguyen S, Quach P, Orvis A, Furuta A, Johansson-Lindbom B, Fischer PB, Rajagopal L. A Recombinant Alpha-Like Protein Subunit Vaccine (GBS-NN) Provides Protection in Murine Models of Group B Streptococcus Infection. J Infect Dis 2022; 226:177-187. [PMID: 35429401 PMCID: PMC9890916 DOI: 10.1093/infdis/jiac148] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 04/11/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Group B Streptococcus (GBS) transmission during pregnancy causes preterm labor, stillbirths, fetal injury, or neonatal infections. Rates of adult infections are also rising. The GBS-NN vaccine, engineered by fusing N-terminal domains of GBS Alpha C and Rib proteins, is safe in healthy, nonpregnant women, but further assessment is needed for use during pregnancy. Here, we tested GBS-NN vaccine efficacy using mouse models that recapitulate human GBS infection outcomes. METHODS Following administration of GBS-NN vaccine or adjuvant, antibody profiles were compared by ELISA. Vaccine efficacy was examined by comparing infection outcomes in GBS-NN vaccinated versus adjuvant controls during systemic and pregnancy-associated infections, and during intranasal infection of neonatal mice following maternal vaccination. RESULTS Vaccinated mice had higher GBS-NN-specific IgG titers versus controls. These antibodies bound alpha C and Rib on GBS clinical isolates. Fewer GBS were recovered from systemically challenged vaccinated mice versus controls. Although vaccination did not eliminate GBS during ascending infection in pregnancy, vaccinated dams experienced fewer in utero fetal deaths. Additionally, maternal vaccination prolonged neonatal survival following intranasal GBS challenge. CONCLUSIONS These findings demonstrate GBS-NN vaccine efficacy in murine systemic and perinatal GBS infections and suggest that maternal vaccination facilitates the transfer of protective antibodies to neonates.
Collapse
Affiliation(s)
- Alyssa Brokaw
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA,Department of Global Health, University of Washington, Seattle, Washington, USA
| | - Shayla Nguyen
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Phoenicia Quach
- Present affiliation: Phoenicia Quach, Universal Cells, Seattle 98121, Washington
| | - Austyn Orvis
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Anna Furuta
- Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, Washington, USA,Department of Global Health, University of Washington, Seattle, Washington, USA
| | | | | | - Lakshmi Rajagopal
- Correspondence: L. Rajagopal, PhD, Department of Pediatrics, University of Washington, Seattle Children’s Hospital Research Institute, 307 Westlake Ave N, Seattle, WA 98109 ()
| |
Collapse
|
14
|
Chong A, Wahi S, Cox S, Nguyen S, Robinson J, Mew T, Singh S, Singbal Y. Echocardiographic vs Invasive Estimation of Left Atrial Pressure – Ongoing Search for the Holy Grail. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Moroz M, Ostiguy G, Delvaux F, Nuehrenboerger C, Nguyen S, Kaux JF, Schindler M, Seil R, Martens G. Le développement athlétique des jeunes : synthèse ReFORM de la position de consensus du CIO. Sci Sports 2022. [DOI: 10.1016/j.scispo.2021.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Nguyen S, Van de Perre E, Velkeniers B, Pierret L, Gutermuth J, Grosber M. Resolution of idiopathic erythema gyratum repens with acitretin. J Eur Acad Dermatol Venereol 2021; 36:e300-e302. [PMID: 34863008 DOI: 10.1111/jdv.17851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S Nguyen
- Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| | - E Van de Perre
- Department of Nephrology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| | - B Velkeniers
- Department of Endocrinology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| | - L Pierret
- Dr. Pierret Dermatoloog Dworp, Dworp, Belgium
| | - J Gutermuth
- Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| | - M Grosber
- Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| |
Collapse
|
17
|
Hickey C, Nguyen S, Anes J, Hurley D, Donoghue O, Fanning S, Schaffer K. Differences in antimicrobial susceptibility testing complicating management of IMP carbapenemase-producing Enterobacterales infection. J Glob Antimicrob Resist 2021; 27:284-288. [PMID: 34775131 DOI: 10.1016/j.jgar.2021.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 09/02/2021] [Accepted: 09/29/2021] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES IMP-type carbapenemases are rarely detected in Europe and limited information is available to guide the treatment of infections caused by carbapenemase-producing Enterobacterales (CPE) producing these carbapenemases. Accurate antimicrobial susceptibility testing (AST) results are essential for optimal antibiotic management. Here we report discrepancies in AST of IMP-producing Enterobacterales (IMP-CPE) complicating the management of severe sepsis. METHODS Antimicrobial susceptibilities were analysed by in-house VITEK® 2, Etest and broth microdilution (BMD). Carbapenemase-encoding genes were detected by PCR. Whole-genome sequencing (WGS) was performed using an Illumina MiSeq platform. RESULTS Minimum inhibitory concentrations (MICs) determined by VITEK® 2 for Enterobacter hormaechei and Klebsiella oxytoca blood culture isolates were ≥16 mg/L for meropenem and ≤0.5 mg/L for ertapenem. In contrast, Etest analysis and BMD returned MICs of 2 mg/L and 1 mg/L, respectively. Both isolates tested positive for IMP carbapenemase-encoding genes by PCR. WGS revealed that both isolates carried the same blaIMP-4 gene. Based on VITEK® 2 susceptibilities, initial treatment was with tigecycline and amikacin. After subsequent deterioration, the patient was successfully treated with ertapenem and amikacin. CONCLUSION This case highlights that automated AST by VITEK® 2 can over-report meropenem resistance for IMP carbapenemase-producers compared with Etest and BMD. Clinicians need to be cautious deciding against carbapenem treatment based on VITEK® 2 susceptibility testing results for IMP-positive Enterobacterales. Tigecycline was inferior to carbapenem treatment for pyelonephritis caused by isolates expressing IMP carbapenemases, however specific evidence guiding the treatment of these infections is lacking.
Collapse
Affiliation(s)
- C Hickey
- School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland; Department of Clinical Microbiology, St Vincent's University Hospital, Elm Park, Dublin D04 T6F4, Ireland
| | - S Nguyen
- School of Public Health, Physiotherapy & Sports Science, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - J Anes
- School of Public Health, Physiotherapy & Sports Science, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - D Hurley
- School of Public Health, Physiotherapy & Sports Science, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - O Donoghue
- Department of Clinical Microbiology, St Vincent's University Hospital, Elm Park, Dublin D04 T6F4, Ireland
| | - S Fanning
- School of Public Health, Physiotherapy & Sports Science, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - K Schaffer
- School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland; Department of Clinical Microbiology, St Vincent's University Hospital, Elm Park, Dublin D04 T6F4, Ireland.
| |
Collapse
|
18
|
Todd J, Thomas P, Nguyen S. Cyclophosphamide and prednisolone for chemotherapy naïve B cell multicentric lymphoma in dogs: 32 cases (2017-2021). J Small Anim Pract 2021; 63:52-55. [PMID: 34647324 DOI: 10.1111/jsap.13428] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 07/20/2021] [Accepted: 08/26/2021] [Indexed: 12/24/2022]
Abstract
OBJECTIVES The aim of this study was to characterise the response rate and toxicity profile of cyclophosphamide and prednisolone given to dogs with newly diagnosed, chemotherapy naïve, B cell multicentric lymphoma. MATERIALS AND METHODS Dogs with diagnosed with B cell lymphoma naïve to chemotherapy treatment were prospectively identified at the author's institution (2017 to 2021) and given cyclophosphamide as their initial chemotherapeutic agent in combination with prednisolone with owner's consent. Signalment, laboratory findings, stage, treatment response and toxicity were recorded. RESULTS Thirty-two dogs were included in the study. The overall response rate in this population of dogs was 84%. Twenty dogs (62%) had a partial response, three dogs (9%) had a complete response, four dogs (12%) had stable disease and five dogs (15%) had progressive disease. Side effects were noted in 47% of patients, with neutropaenia being the most commonly reported. CLINICAL SIGNIFICANCE Cyclophosphamide and prednisolone were well-tolerated with limited side effects. The response rate observed in this cohort of dogs with chemotherapy-naïve B cell multicentric lymphoma is promising. Further comparative studies are required to confirm the safety and effectiveness of this intervention.
Collapse
Affiliation(s)
- J Todd
- Small Animal Specialist Hospital (SASH), 2 Bounty Close, Tuggerah, NSW, 2259, Australia
| | - P Thomas
- Small Animal Specialist Hospital (SASH), 2 Bounty Close, Tuggerah, NSW, 2259, Australia
| | - S Nguyen
- Small Animal Specialist Hospital (SASH), 2 Bounty Close, Tuggerah, NSW, 2259, Australia
| |
Collapse
|
19
|
Mohamud D, Nguyen S, Schawlm J. EARLY DISCHARGE OF PRIMARY PCI PATIENTS. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
20
|
Tran H, Nguyen S, Nguyen K, Pham D, Le A, Nguyen G, Tran D, Shu X, Osarogiagbon R, Tran T. OA18.01 Lung Cancer in Vietnam. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Vitrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, Valran A, Bosch A, Noret M, Delory T. Séroprévalence SARS-Cov-2 chez les professionnels de santé : étude multicentrique avec analyse des facteurs de risque professionnels et extraprofessionnels. Infect Dis Now 2021. [PMCID: PMC8327511 DOI: 10.1016/j.idnow.2021.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Introduction L’objectif de notre étude était d’évaluer la séroprévalence SARS-Cov-2 chez les professionnels de santé, après la première vague Covid-19, et d’analyser les facteurs professionnels et extraprofessionnels modifiant cette prévalence. Matériels et méthodes Suite aux instructions gouvernementales proposant de réaliser une sérologie Covid-19 à tout professionnel de santé après la première vague, nous avons réalisé une étude transversale, multicentrique. Tous les professionnels volontaires des quatre centres participants étaient invités à réaliser une sérologie et à remplir un questionnaire concernant leurs données démographiques, leurs caractéristiques professionnelles, l’utilisation des équipements de protection individuelle et l’exposition extra professionnelle au Covid-19. Nous avons calculé la prévalence SARS-Cov-2 et utilisé une régression logistique en appliquant un effet centre. Résultats Un total de 3454 professionnels ont participé à l’étude dont 83,4 % de femmes. L’âge moyen était de 40,6 ans [31,8–50,3]. En médiane, la prévalence sérologique SARS-Cov-2 était de 5 % (95 % IC, 4,3 %–5,8 %). Les facteurs associés à une plus forte séroprévalence étaient : l’âge < 30 ans (aOR = 1,59, (95 % IC, 1,06–2,37)), le statut d’étudiant (aOR = 3,38, (95 % IC, 1,62–7,05)) avec une séroprévalence de 16,9 % dans cette catégorie. L’unité de travail, y compris le fait d’avoir travaillé en unité Covid ou en réanimation, ainsi que l’exposition à des patients (quel que soit leur statut infectieux) n’étaient pas associé à une augmentation de la séroprévalence. Par contre les professionnels rapportant un contact avec un patient Covid, sans protection adaptée, ou ayant pratiqué des taches aérosolisantes, y compris avec un masque FFP2, avaient un surrisque d’infection Covid-19 (respectivement aOR à 1,66 et 1,7). Enfin, l’exposition à un collègue infecté ou à un cas familial était également associée à une augmentation de la prévalence sérologique. Conclusion Les mesures mises en place pour limiter la transmission du SARS-Cov-2 des patients aux professionnels de santé semblent efficaces. En complément de la vaccination, l’éviction systématique des professionnels infectés, la formation des étudiants et le rappel des mesures d’hygiène durant les temps de pause pourraient limiter la contamination des professionnels de santé.
Collapse
|
22
|
Laurent A, Nguyen S, Leclerc P, Capellier G. L’enfant visiteur en réanimation adulte : vécu psychologique de la visite et dispositifs d’accompagnement. PRAT PSYCHOL 2021. [DOI: 10.1016/j.prps.2020.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Delaloge S, Dureau S, D'Hondt V, Desmoulins I, Heudel PE, Duhoux F, Levy C, Lerebours F, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Callens C, Gentien D, Manduzio H, Vincent-Salomon A, Lemonnier J, Cottu P. 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
24
|
Lembong J, O’Rourke B, Sears T, Nguyen S, Barnett C, Salmi M, Kombe M, Getz J, Garg P, Whitelonis A, Rowley J, Cap B, Barcia R. Large scale manufacturing and potency assay development for hmscs in regenerative medicine. Cytotherapy 2021. [DOI: 10.1016/s1465324921005508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Noizet M, Gottwalles Y, Nguyen S, Thibaud E, Labrosse F, Delmas N, Vilbois E, Marchetto J, Heymonet S. Retour d’expérience de deux structures d’urgences de centres hospitaliers généraux pendant la crise de la Covid-19. Ann Fr Med Urgence 2020. [DOI: 10.3166/afmu-2020-0263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
La Covid-19 s’est abattue sur l’Alsace en quelques jours, mettant à mal les hôpitaux de Mulhouse et de Colmar. Bien que proches, des différences notables existent au sein de ces deux structures en termes architecturaux et de ressources humaines. Comment cette vague a-t-elle modifié les organisations de chacun ? Quelles alternatives ont pu être mises en place ? Après la présentation de chaque site sont analysées les adaptations nécessaires afin d’absorber les flux de patients et leur proposer une prise en charge décente malgré des conditions parfois très dégradées. Nouvelles filières, modifications organisationnelles, renforts de personnel en interne puis en externe, augmentation capacitaire nette, recherches de solutions alternatives aux voies classiques d’approvisionnement des matériels… ont été une partie de la solution. Malgré les alertes du terrain, l’action nationale est restée en décalage de compréhension de la gravité de la situation locale, avec des recommandations et des actions soit inapplicables, soit trop tardives. Les établissements et professionnels de santé ont eu un sentiment d’isolement, renforcé par l’absence de représentant des tutelles et notamment de l’Agence régionale de santé sur le terrain. Deux éléments majeurs peuvent être mis en avant : une cohésion majeure de l’ensemble du centre hospitalier avec travail d’équipe et de terrain entre soignants et direction, et une implication de l’ensemble des acteurs de la médecine d’urgence (public, privé, libéraux, service départemental d’incendie et de secours) ; ils ont été les déterminants dans notre capacité à faire face à cet événement inédit.
Collapse
|
26
|
Lafraire J, Rioux C, Hamaoui J, Girgis H, Nguyen S, Thibaut JP. Food as a borderline domain of knowledge: The development of domain-specific inductive reasoning strategies in young children. Cognitive Development 2020. [DOI: 10.1016/j.cogdev.2020.100946] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Nguyen S, Wallard P, Oddoux O, Descamps D. Caractéristiques cliniques et pronostiques des bactériémies à Staphylococcus aureus dans un centre hospitalier général. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Frenel JS, Dalenc F, Pistilli B, de La Motte Rouge T, Levy C, Mouret-Reynier MA, Hardy-Bessard AC, Bonichon-Lamichhane N, Greilsamer C, Delecroix V, Nguyen S, Berger F, Everhard S, Lemonnier J, Loirat D, Callens C, Pradines A, Bachelot T, Delaloge S, Bidard F. 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.406] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Wallard P, Nguyen S, Robineau O, Descamps D, Senneville E. Prise en charge de l’ostéite du pied diabétique par chirurgie conservatrice. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
McMaster A, Helms A, Nguyen S, Preston S, Brazzale A, Starmer G. 867 Percutaneous Intervention to Saphenous Vein Graft in Far North Queensland; Feasibility and Safety in a Regional Centre. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Nguyen S, Arriaga Castellanos K, Abraham A, Rajfer J, Ferrini M. 169 COMP-4 Reduces Oxidative Stress Markers in the Rat Corpora Cavernosa and Media of the Penile Dorsal Artery. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2019.11.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Maffey M, Nguyen S, Wahi S. 414 The Diagnostic Value of Inpatient Transthoracic Echocardiography for Stroke and TIA. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol 2019; 29:2334-2340. [PMID: 30307466 DOI: 10.1093/annonc/mdy448] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. Patients and methods NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)×3 21-day courses followed by docetaxel 100 mg/m2×3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety. Results Overall, 106 patients were randomised [median Prosigna® ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7.7% (95% CI 0.4-14.9)] and chemotherapy [15.7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm). Conclusion LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna®-defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less favourable safety profile. LETPAL combination might represent an alternative to chemotherapy in early high-risk LBC. Clinical Trial Number NCT02400567.
Collapse
Affiliation(s)
- P Cottu
- Department of Medical Oncology, Institut Curie, Paris, France; Paris Sciences et Lettres University, Paris, France.
| | - V D'Hondt
- Department of Medical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - S Dureau
- Department of Biometry, Institut Curie, Saint-Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Saint-Cloud, France
| | - I Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - P-E Heudel
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - F P Duhoux
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - C Levy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - M-A Mouret-Reynier
- Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - F Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Toulouse, France
| | - J-S Frenel
- Department of Medical Oncology, ICO Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France
| | - C Jouannaud
- Department of Medical Oncology, Institut Jean Godinot, Reims, France
| | - L Venat-Bouvet
- Department of Medical Oncology, Limoges University Hospital, Limoges, France
| | - S Nguyen
- Department of Medical Oncology, Centre Hospitalier de Pau, Pau, France
| | - J-M Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - J-L Canon
- Department of Oncology-Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium
| | - J Grenier
- Department of Medical Oncology, Institut Sainte-Catherine, Avignon, France
| | - C Callens
- Paris Sciences et Lettres University, Paris, France; Pharmacogenomics, Department of Tumor Biology, France
| | - D Gentien
- Paris Sciences et Lettres University, Paris, France; Genomics Platforms, Translational Research Department, Institut Curie, Paris, France
| | | | - A Vincent-Salomon
- Paris Sciences et Lettres University, Paris, France; Tumour Biology Department, Institut Curie, Paris, France
| | - S Delaloge
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
34
|
Marques C, Nguyen S, Chiu R, Olch A, Chang E, Ballas L, Wong K. Comparison of Workflow Efficiency of VMAT Craniospinal Irradiation Between Adult and Pediatric Settings. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Nguyen S, Maaninka K, Mäyränpää I M, Metso J, Jauhiainen M, P. Kovanen T, Öörni K. Neutrophil Protease 3 Is Present In Human Atherosclerotic Lesions And Modifies Ldl And Hdl Particles. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Boucher A, Robineau O, Viget N, Nguyen S, Huleux T, Meybeck A, Senneville E, Celia S, Ajana F. Évaluation du statut vaccinal des voyageurs dans un centre de vaccinations internationales. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
37
|
Geraldino-Pardilla L, Perel-Winkler A, Miceli J, Neville K, Danias G, Nguyen S, Dervieux T, Kapoor T, Giles J, Askanase A. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus 2019; 28:862-867. [PMID: 31122136 DOI: 10.1177/0961203319851558] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES Hydroxychloroquine (HCQ) is a key therapy in systemic lupus erythematosus (SLE). Medication non-adherence is reported in up to 80% of lupus patients and results in increased morbidity, mortality, and health care utilization. HCQ levels are a sensitive and reliable method to assess medication adherence. Our study evaluated the role of HCQ level measurement in routine clinical care and its association with disease activity in a predominantly Hispanic population. METHODS SLE patients from the Columbia University Lupus cohort treated with HCQ for ≥ 6 months and reporting medication adherence were included. HCQ levels were measured by whole blood high performance liquid chromatography. Non-adherence was defined as an HCQ level <500 ng/ml. The association between HCQ levels and disease activity measured by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) was evaluated. RESULTS One hundred and eight patients were enrolled; the median age was 38 years, 91% were female, and 63% were Hispanic. The median SLEDAI-2K was 4.3 (0-20). Forty-one percent of patients had an HCQ level <500 ng/ml consistent with non-adherence, of which 19% had undetectable levels. A higher SLEDAI-2K score was associated with low HCQ levels (p = 0.003). This association remained significant after adjusting for depression (p = 0.0007). CONCLUSION HCQ levels < 500 ng/ml were associated with higher disease activity and accounted for 32% of the SLEDAI-2K variability. HCQ blood measurement is a simple and reliable method to evaluate medication adherence in SLE. Reasons for non-adherence (levels < 500 ng/ml) should be further explored and addressed.
Collapse
Affiliation(s)
- L Geraldino-Pardilla
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - A Perel-Winkler
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - J Miceli
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - K Neville
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - G Danias
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - S Nguyen
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | | | - T Kapoor
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - J Giles
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| | - A Askanase
- 1 Division of Rheumatology, Columbia University College of Physicians and Surgeons, and New York Presbyterian Hospital, New York, USA
| |
Collapse
|
38
|
Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer 2019; 22:577-586. [PMID: 30311042 DOI: 10.1007/s10120-018-0885-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 10/01/2018] [Indexed: 02/07/2023]
Abstract
AIM The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. METHODS In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. RESULTS Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0-1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/mm3; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09-2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41-4.84, p = 0.005) were the only significant poor prognostic factors for OS. CONCLUSION Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.
Collapse
Affiliation(s)
- Y Touchefeu
- Gastrointestinal Oncology Unit, Institut des Maladies de l'Appareil Digestif, University Hospital, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France.
| | - R Guimbaud
- Digestive Medical Oncology IUCT Rangueil, CHU de Toulouse, Toulouse, France
| | - C Louvet
- Oncology Multidisciplinary Research Group (GERCOR), 151 rue du Faubourg Saint Antoine, 75011, Paris, France
| | - L Dahan
- Digestive Oncology Unit, AP-HM, La Timone Hospital, Aix-Marseille Université, Marseille, France
| | - E Samalin
- Digestive Oncology Department, Institut du Cancer de Montpellier, Montpellier, France
| | - E Barbier
- Fédération Francophone de Cancérologie Digestive-EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France
| | - K Le Malicot
- Fédération Francophone de Cancérologie Digestive-EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France
| | - R Cohen
- Department of Oncology, Sorbonne Université, AP-HP, hôpital Saint-Antoine, 75012, Paris, France
| | - J M Gornet
- Department of Gastroenterology, AP-HP Hôpital Saint Louis, Paris, France
| | - T Aparicio
- Department of Gastroenterology and Digestive Oncology, Saint Louis Hospital, APHP, University Denis Diderot, Sorbonne Paris Cité, Paris, France
| | - S Nguyen
- Oncology Multidisciplinary Research Group (GERCOR), 151 rue du Faubourg Saint Antoine, 75011, Paris, France
| | - A Azzedine
- Department of oncology, CH Montélimar, Montélimar, France
| | - P L Etienne
- Oncology Department, CARIO, HPCA, Plérin, France
| | - J M Phelip
- Service HGE et Oncologie Digestive, CHU de Saint Etienne, Unité HESPER EA-7425 Université Jean Monnet/Claude Bernard Lyon 1, Villeurbanne, France
| | - P Hammel
- Digestive Oncology Unit, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France
| | - N Chapelle
- Gastrointestinal Oncology Unit, Institut des Maladies de l'Appareil Digestif, University Hospital, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - D Sefrioui
- Digestive Oncology Unit, Department of Hepato-Gastroenterology, Rouen University Hospital, UNIROUEN, Inserm U1245, IRON group, Normandie University, 76000, Rouen, France
| | - L Mineur
- Institut Sainte Catherine, Avignon, France
| | - C Lepage
- Gastroenterology Department, INSERM UMR1231, CHU de Dijon, University Bourgogne Franche-Comté, Dijon, France
| | - O Bouche
- Digestive Oncology, CHU REIMS, Reims, France
| |
Collapse
|
39
|
Gentilleau-Lambin P, Nicli J, Richard AF, Macchi L, Barbeau C, Nguyen S, Medjkane F, Lemaître MP. Assessment of conversational pragmatics: A screening tool for pragmatic language impairment in a control population of children aged 6-12 years. Arch Pediatr 2019; 26:214-219. [PMID: 30954368 DOI: 10.1016/j.arcped.2019.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 02/12/2019] [Accepted: 03/07/2019] [Indexed: 10/27/2022]
Abstract
Pragmatics can be defined as the way in which language is used to communicate in a given social context. Although there is a lack of a standardized assessment, healthcare professionals find themselves confronted with pragmatic language skill impairments in children with neurodevelopmental disorders or brain injuries. The characterization of language use causes problems in social interactions, which has clinical implications in daily life. However, this is still underestimated because there is currently no quick, easy-to-use screening device to rank these deficits. We have developed a pragmatic deficits screening chart that has been tested on a control population of children aged 6-12 years. The chart comprises 26 items exploring seven areas of pragmatics (intentionality, governance of exchange, organization of information, adaptation strategies, conversational implicit language, nonverbal skills, and paralinguistic aspects). Parents select one of four possible answers to describe how frequently their child demonstrates each type of behavior ("never, rarely, sometimes, often"). We distributed 1666 charts; 760 were returned, of which 552 could be analyzed. Internal consistency as measured with Cronbach's alpha coefficient (0.88) was satisfactory. There was no influence of age on total score, nor of the department/type of schooling. The population distribution was non-Gaussian so the results are presented in percentiles. We propose a first-line screening tool that is quick and easy to complete by family, which facilitates referral to specialists for further investigations into the etiological implications of pragmatic language impairment.
Collapse
Affiliation(s)
- P Gentilleau-Lambin
- Regional Diagnosis Center for Learning Difficulties (CRDTA), Centre Paul-Boulanger, CHU de Lille, 59037 Lille cedex, France.
| | - J Nicli
- Regional Diagnosis Center for Learning Difficulties (CRDTA), Centre Paul-Boulanger, CHU de Lille, 59037 Lille cedex, France
| | - A-F Richard
- Private speech therapy practice, 9, rue des Buttes, 92220 Bagneux, France
| | - L Macchi
- Regional Diagnosis Center for Learning Difficulties (CRDTA), Centre Paul-Boulanger, CHU de Lille, 59037 Lille cedex, France; Laboratoire Savoirs, Textes, Langage (STL), CNRS, UMR 8163, Université de Lille, 59653 Villeneuve d'Ascq, France
| | - C Barbeau
- Reference Center for Rare Diseases (CRMR), Centre Paul-Boulanger, CHU de Lille, 59037 Lille cedex, France
| | - S Nguyen
- Department of Neuropediatrics, CHU de Lille, Hôpital Roger-Salengro, 59037 Lille cedex, France
| | - F Medjkane
- Department of Child and Adolescent Psychiatry, CHU de Lille, Hôpital Fontan, 59037 Lille cedex, France
| | - M-P Lemaître
- Regional Diagnosis Center for Learning Difficulties (CRDTA), Centre Paul-Boulanger, CHU de Lille, 59037 Lille cedex, France
| |
Collapse
|
40
|
Rajfer J, Nguyen S, Shaheen M, Pak Y. 167 Improvement in SHIM Scores with the iNOS Stimulator, Revactin®. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.01.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Ferrini M, Abraham A, Nguyen S, Flores M, Luna R, Artaza J, Rajfer J. 076 Exogenous Administration of L-arginine Does Not Stimulate the Endogenous NO-cGMP Pathway in Rat Penile Corpora Smooth Muscle Cells. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.01.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Nguyen S, Luna R, Ferrini M. 189 Electronic Cigarette Smoke and Western Diet in Erectile Dysfunction: Histological Changes in Mice Corpora Cavernosa. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.01.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Joseph C, Robineau O, Titecat M, Putman S, Blondiaux N, Loiez C, Valette M, Schmit JL, Beltrand E, Dézeque H, Nguyen S, Migaud H, Senneville E. Daptomycin versus Vancomycin as Post-Operative Empirical Antibiotic Treatment for Prosthetic Joint Infections: A Case-Control Study. J Bone Jt Infect 2019; 4:72-75. [PMID: 31011511 PMCID: PMC6470651 DOI: 10.7150/jbji.22118] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 06/16/2018] [Indexed: 12/31/2022] Open
Abstract
Purpose: To compare safety and efficacy of Vancomycin (Van) versus Daptomycin (Dap) as post-operative empirical antibiotic treatment (PEAT) in patients with periprosthetic joint infections (PJIs). Methods: Medical charts of patients treated empirically with Van or Dap in the post-operative period of total hip/knee prosthesis septic revision until the results of intra-operative culture were reviewed. Cefotaxime, cefepime or aztreonam were used in combination with Dap or Van. Results: Twenty Dap patients were matched with 20 other Van patients according to the age and type of prosthesis. The ASA score and the distribution of the pathogens was similar in the two groups especially regarding the number of methicillin-resistant staphylococci. The mean duration of the PEAT was 6.07 ± 0.85 days. A total of 17 episodes of adverse events (AE) in 10 patients (25%) were recorded during the PEAT which led to discontinue the treatment in 5 patients, all of them treated with Van (P=0.02). At the end of a mean post-treatment follow-up of 618 +/- 219 days, 36 patients remained in remission of infection; 2 patients failed in each group. Conclusions: Our observations suggest that PEAT with Van for septic revision of PJIs is associated with a higher discontinuation rate due to AE but with a similar outcome than it is with Dap.
Collapse
Affiliation(s)
- C Joseph
- Infectious Diseases Department, University Hospital of Amiens, France
| | - O Robineau
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France.,Faculty of Medicine of Lille, Lille University 2
| | - M Titecat
- Faculty of Medicine of Lille, Lille University 2.,Laboratory of Microbiology, University Hospital of Lille, France
| | - S Putman
- Orthopaedic Surgery Unit, University Hospital of Lille, France
| | - N Blondiaux
- Laboratory of Microbiology, Gustave Dron Hospital of Tourcoing, France
| | - C Loiez
- Laboratory of Microbiology, University Hospital of Lille, France
| | - M Valette
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France
| | - J L Schmit
- Infectious Diseases Department, University Hospital of Amiens, France
| | - E Beltrand
- Orthopedic Surgery Unit, Gustave Dron Hospital, France
| | - H Dézeque
- Orthopaedic Surgery Unit, University Hospital of Lille, France
| | | | - H Migaud
- Faculty of Medicine of Lille, Lille University 2.,Orthopaedic Surgery Unit, University Hospital of Lille, France
| | - E Senneville
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France.,Faculty of Medicine of Lille, Lille University 2.,Orthopaedic Surgery Unit, University Hospital of Lille, France
| |
Collapse
|
44
|
Sullivan I, Nguyen S, Harris B, Rivera V, Panzer K, Moon J, Chen S, Lu X, Patel N, Cohen G, Yu D, Panaro J. 03:18 PM Abstract No. 375 Post-lung biopsy pneumothorax: a single-center experience. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
45
|
Ponsford J, Nguyen S, Downing M, Bosch M, McKenzie J, Turner S, Chau M, Mortimer D, Gruen R, Knott J, Green S. Factors associated with persistent post-concussion symptoms following mild traumatic brain injury in adults. J Rehabil Med 2019; 51:32-39. [DOI: 10.2340/16501977-2492] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
46
|
Shourick J, Vesinet C, Monsel A, Le Pelletier F, Bories D, Barrou B, Nguyen S, Calmus Y, Lebrun-Vignes B, Barete S. GVH aiguë post-transplantation hépatique simulant une nécrolyse épidermique toxique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Bachet J, Lucidarme O, Levache C, Barbier E, Raoul J, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse J, Di Fiore F, Etienne P, Dupuis O, Aleba A, Lepage C, Taieb J, Dahan L, Auby D, Khemissa F, Ghiringhelli F, Nguyen S, Bedjaoui A, Terrebonne E, Thaury J, Baconnier M. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. Eur J Cancer 2018; 104:108-116. [DOI: 10.1016/j.ejca.2018.09.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 08/20/2018] [Accepted: 09/09/2018] [Indexed: 01/29/2023]
|
48
|
Cho Y, Nguyen S, Harkins G, Deimling T. An Analysis of Patients Undergoing Surgical Removal of Essure Device - A Retrospective Case Series. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Brousse K, Nguyen S, Gillet A, Pinaud S, Tan R, Meffre A, Soulantica K, Chaudret B, Taberna P, Respaud M, Simon P. Laser-scribed Ru organometallic complex for the preparation of RuO2 micro-supercapacitor electrodes on flexible substrate. Electrochim Acta 2018. [DOI: 10.1016/j.electacta.2018.05.198] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
50
|
Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF, Adenis A, Alessio A, Aouakli A, Azzedine A, Bedjaoui A, Bidault A, Blanchi A, Botton A, Cadier-Lagnes A, Fatisse A, Gagnaire A, Gilbert A, Gueye A, Hollebecque A, Lemaire A, Mahamat A, Marre A, Patenotte A, Rotenberg A, Roussel A, Thirot-Bidault A, Votte A, Weber A, Zaanan A, Dupont-Gossart A, Villing A, Queuniet A, Coudert B, Denis B, Garcia B, Lafforgue B, Landi B, Leduc B, Linot B, Paillot B, Rhein B, Winkfield B, Barberis C, Becht C, Belletier C, Berger C, Bineau C, Borel C, Brezault C, Buffet C, Cornila C, Couffon C, De La Fouchardière C, Giraud C, Lecaille C, Lepere C, Lobry C, Locher C, Lombard-Bohas C, Paoletti C, Platini C, Rebischung C, Sarda C, Vilain C, Briac-Levaché C, Auby D, Baudet-Klepping D, Bechade D, Besson D, Cleau D, Festin D, Gargot D, Genet D, Goldfain D, Luet D, Malka D, Peré-Vergé D, Pillon D, Sevin-Robiche D, Smith D, Soubrane D, Tougeron D, Zylberait D, Carola E, Cuillerier E, Dorval Danquechin E, Echinard E, Janssen E, Maillard E, Mitry E, Norguet-Monnereau E, Suc E, Terrebonne E, Zrihen E, Pariente E, Almaric F, Audemar F, Bonnetain F, Desseigne F, Dewaele F, Di Fiore F, Ghiringhelli F, Husseini F, Khemissa F, Kikolski F, Morvan F, Petit-Laurent F, Riot F, Subtil F, Zerouala-Boussaha F, Caroli-Bosc F, Boilleau-Jolimoy G, Bordes G, Cavaglione G, Coulanjon G, Deplanque G, Gatineau-Saillant G, Goujon G, Medinger G, Roquin G, Brixi-Benmansour H, Castanie H, Lacroix H, Maechel H, Perrier H, Salloum H, Senellart H, Baumgaertner I, Cumin I, Graber I, Trouilloud I, Boutin J, Butel J, Charneau J, Cretin J, Dauba J, Deguiral J, Egreteau J, Ezenfis J, Forestier J, Goineau J, Lacourt J, Lafon J, Martin J, Meunier J, Moreau J, Provencal J, Taieb J, Thaury J, Tuaillon J, Vergniol J, Villand J, Vincent J, Volet J, Bachet J, Barbare J, Souquet J, Grangé J, Dor J, Paitel J, Jouve J, Raoul J, Cheula J, Gornet J, Sabate J, Vantelon J, Vaillant J, Aucouturier J, Barbieux J, Herr J, Lafargue J, Lagasse J, Latrive J, Plachot J, Ramain J, Robin J, Spano J, Douillard J, Beerblock K, Bouhier-Leporrier K, Slimane Fawzi K, Cany L, Chone L, Dahan L, Gasnault L, Rob L, Stefani L, Wander L, Baconnier M, Ben Abdelghani M, Benchalal M, Blasquez M, Carreiro M, Charbit M, Combe M, Duluc M, Fayolle M, Gignoux M, Giovannini M, Glikmanas M, Mabro M, Mignot M, Mornet M, Mousseau M, Mozer M, Pauwels M, Pelletier M, Porneuf M, Ramdani M, Schnee M, Tissot M, Zawadi M, Clavero-Fabri M, Gouttebel M, Kaminsky M, Galais M, Abdelli N, Barrière N, Bouaria N, Bouarioua N, Delas N, Gérardin N, Hess-Laurens N, Stremsdoerfer N, Berthelet O, Boulat O, Capitain O, Favre O, Amoyal P, Bergerault P, Burtin P, Cassan P, Chatrenet P, Chiappa P, Claudé P, Couzigou P, Feydy P, Follana P, Geoffroy P, Godeau P, Hammel P, Laplaige P, Lehair P, Martin P, Novello P, Pantioni P, Pienkowski P, Pouderoux P, Prost P, Ruszniewski P, Souillac P, Texereau P, Thévenet P, Haineaux P, Benoit R, Coriat R, Lamy R, Mackiewicz R, Beorchia S, Chaussade S, Hiret S, Jacquot S, Lavau Denes S, Montembault S, Nahon S, Nasca S, Nguyen S, Oddou-Lagraniere S, Pesque-Penaud S, Fratte S, Chatellier T, Mansourbakht T, Morin T, Walter T, Boige V, Bourgeois V, Derias V, Guérin-Meyer V, Hautefeuille V, Jestin Le Tallec V, Lorgis V, Quentin V, Sebbagh V, Veuillez V, Adhoute X, Coulaud X, Becouarn Y, Coscas Y, Courouble Y, Le Bricquir Y, Molin Y, Rinaldi Y, Lam Y, Ladhib Z. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Eur J Cancer 2018; 98:1-9. [DOI: 10.1016/j.ejca.2018.03.031] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 03/26/2018] [Accepted: 03/28/2018] [Indexed: 02/07/2023]
|